Reference

1. Oparil, S., Acelajado, M. C., Bakris, G. L., Berlowitz, D. R., Cífková, R., Dominiczak, A. F., Grassi, G., Jordan, J., Poulter, N. R., Rodgers, A., & Whelton, P. K. (2018). Hypertension. Nature reviews. Disease primers, 4, 18014. https://doi.org/10.1038/nrdp.2018.14
2. Yao, K., Nagashima, K., & Miki, H. (2006). Pharmacological, pharmacokinetic, and clinical properties of benidipine hydrochloride, a novel, long-acting calcium channel blocker. Journal of pharmacological sciences, 100(4), 243–261. https://doi.org/10.1254/jphs.dtj05001x
3. Koçak, M. N., Arslan, R., Albayrak, A., Tekin, E., Bayraktar, M., Çelik, M., Kaya, Z., Bekmez, H., &Tavaci, T. (2021). An antihypertensive agent benidipine is an effective neuroprotective and antiepileptic agent: an experimental rat study. Neurological research, 43(12), 1069–1080. https://doi.org/10.1080/01616412.2021.1949685
4. Yang, Y., Chen, W., Wen, N., Cai, C., Liu, Q. H., & Shen, J. (2019). Benidipine, an anti-hypertensive drug, relaxes mouse airway smooth muscle. Life sciences, 227, 74–81. https://doi.org/10.1016/j.lfs.2019.04.036
5. Akinaga, S., Kobayashi, H., Kobayashi, S., Inoue, A., Nakamizo, N., & Oka, T. (1988). Determination of the calcium antagonist benidipine hydrochloride in plasma by sensitive radioimmunoassay. Arzneimittel-Forschung, 38(11A), 1738–1741.
6. Matsunaka, K., Imai, M., Sanda, K., Yasunami, N., Furuhashi, A., Atsuta, I., Wada, H., & Ayukawa, Y. (2022). Therapeutic Effect of Benidipine on Medication-Related Osteonecrosis of the Jaw. Pharmaceuticals (Basel, Switzerland), 15(8), 1020. https://doi.org/10.3390/ph15081020
7. Ma, Z. P., Liao, J. C., Zhao, C., & Cai, D. Z. (2015). Effects of the 1, 4-dihydropyridine L-type calcium channel blocker benidipine on bone marrow stromal cells. Cell and tissue research, 361(2), 467–476. https://doi.org/10.1007/s00441-015-2115-x
8. Cakir, T., Yucetas, S. C., Yazici, G. N., Sunar, M., Arslan, Y. K., & Suleyman, H. (2021). Effects of Benidipine Hydrochloride on Ischemia Reperfusion Injury of Rat Brain. Turkish neurosurgery, 31(3), 310–317. https://doi.org/10.5137/1019-5149.JTN.27372-19.3
9. Liu, H. R., Gao, F., Tao, L., Yan, W. L., Gao, E., Christopher, T. A., Lopez, B. L., Hu, A., & Ma, X. L. (2004). Antiapoptotic mechanisms of benidipine in the ischemic/reperfused heart. British journal of pharmacology, 142(4), 627–634. https://doi.org/10.1038/sj.bjp.0705847
10. Yao, K., Ina, Y., Sonoda, R., Nagashima, K., Ohmori, K., & Ohno, T. (2003). Protective effects of benidipine on hydrogen peroxide-induced injury in rat isolated hearts. The Journal of pharmacy and pharmacology, 55(1), 109–114. https://doi.org/10.1111/j.2042-7158.2003.tb02440.x
11. Kazama, I., Baba, A., Matsubara, M., Endo, Y., Toyama, H., &Ejima, Y. (2014). Benidipine suppresses in situ proliferation of leukocytes and slows the progression of renal fibrosis in rat kidneys with advanced chronic renal failure. Nephron. Experimental nephrology, 128(1-2), 67–79. https://doi.org/10.1159/000368080
12. Wu, G., Xu, M., Xu, K., & Hu, Y. (2013). Benidipine protects kidney through inhibiting ROCK1 activity and reducing the epithelium-mesenchymal transdifferentiation in type 1 diabetic rats. Journal of diabetes research, 2013, 174526. https://doi.org/10.1155/2013/174526
13. Abe, M., Okada, K., Maruyama, N., Matsumoto, S., Maruyama, T., Fujita, T., Matsumoto, K., & Soma, M. (2011). Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. Hypertension research : official journal of the Japanese Society of Hypertension, 34(2), 268–273. https://doi.org/10.1038/hr.2010.221
14. Ohta, M., Sugawara, S., Sato, N., Kuriyama, C., Hoshino, C., & Kikuchi, A. (2009). Effects of benidipine, a long-acting T-type calcium channel blocker, on home blood pressure and renal function in patients with essential hypertension: a retrospective, 'real-world' comparison with amlodipine. Clinical drug investigation, 29(11), 739–746. https://doi.org/10.2165/11320000-000000000-00000
15. Makino, H., Aoki, M., Hashiya, N., Yamasaki, K., Shimizu, H., Miwa, K., Ogihara, T., & Morishita, R. (2005). A calcium-channel blocker, benidipine, improves forearm reactive hyperemia in patients with essential hypertension. Blood pressure. Supplement, 1, 39–44. https://doi.org/10.1080/08038020510040612
16. Matsubara, M., & Hasegawa, K. (2004). Effects of benidipine, a dihydropyridine-Ca2+ channel blocker, on expression of cytokine-induced adhesion molecules and chemoattractants in human aortic endothelial cells. European journal of pharmacology, 498(1-3), 303–314. https://doi.org/10.1016/j.ejphar.2004.07.086
17. Wang, B., Yang, J., Fan, L., Wang, Y., Zhang, C., & Wang, H. (2021). Osteogenic effects of antihypertensive drug benidipine on mouse MC3T3-E1 cells in vitro. Journal of Zhejiang University. Science. B, 22(5), 410–420. https://doi.org/10.1631/jzus.B2000628
18. Mathew, S. K., Naik, G. S., &Peedicayil, J. (2017). Inhibition by Benidipine of Contractility of Isolated Proximal and Distal Caprine Ureter. International journal of applied & basic medical research, 7(3), 155–159. https://doi.org/10.4103/ijabmr.IJABMR_87_16